

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Nalmefene for reducing alcohol consumption in people with alcohol dependence

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how? |
|---|

No potential equality issues were identified
--

- | |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these? |
|--|

Two potential equality issues have been raised in the expert statements. The first point raised by an expert suggested there may be issues with consent of treatment in certain people in terms of cognitive decline and learning disability. The second issue was raised in an expert statement and during the committee meeting and discussed the issue that some families may be stigmatised for having a family member with alcohol dependency. The Committee considered that healthcare professionals should be mindful of the need to ensure equality of access to treatment for patients with disabilities. The Committee did not consider that the wording of the recommendations affected access to treatment by people with cognitive decline and learning disability. The second issue is not considered to be an equalities issue as defined by equalities legislation.

- | |
|--|
| 3. Have any other potential equality issues been identified by the |
|--|

Committee, and, if so, how has the Committee addressed these?
No

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?
The Committee concluded that its preliminary recommendations do account for the individual needs of people to receive nalmefene, and do not make it more difficult for any particular group to access the treatment with nalmefene compared with any other group.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No

6. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
No

7. Have the Committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?
Yes in section 4.12 of the ACD

Approved by Associate Director (name): Helen Knight

Date: 01/07/2014

Final appraisal determination

(when an ACD issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

No

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

No

5. Have the Committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?
Yes in section 4.15

Approved by Centre or Programme Director (name): Meindert Boysen

Date: 06/10/14